Merck set to join forces with Project Data Sphere to pioneer Global Oncology Big Data Alliance
- Details
- Category: Merck Group
Merck, a leading science and technology company has announced that it will enter into a strategic collaboration with Project Data Sphere LLC, an independent, not-for-profit initiative of the CEO Roundtable on Cancer's Life Sciences Consortium, to jointly lead the Global Oncology Big Data Alliance (GOBDA).
Sanofi and Regeneron announce that cemiplimab (REGN2810) has received FDA Breakthrough Therapy designation for advanced cutaneous squamous cell carcinoma
- Details
- Category: Sanofi
Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation status to cemiplimab (REGN2810) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (CSCC) and adults with locally advanced and unresectable CSCC, the second deadliest skin cancer after melanoma[1], [2]. Cemiplimab is an investigational human, monoclonal antibody targeting PD-1.
Merck to acquire Rigontec, RIG-I therapeutics pioneer, advancing leadership in immuno-oncology
- Details
- Category: Merck
Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Rigontec announced that Merck will acquire Rigontec. Rigontec is a pioneer in accessing the retinoic acid-inducible gene I (RIG-I) pathway, part of the innate immune system, as a novel and distinct approach in cancer immunotherapy to induce both immediate and long-term anti-tumor immunity.
Bristol-Myers Squibb completes previously announced acquisition of IFM Therapeutics
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has completed the previously announced planned acquisition of IFM Therapeutics. The transaction includes full rights to IFM's preclinical STING (stimulator of interferon genes) and NLRP3 agonist programs focused on enhancing the innate immune response for treating cancer.
Tezepelumab significantly reduced asthma exacerbations for a broad population of patients with severe uncontrolled asthma
- Details
- Category: AstraZeneca
AstraZeneca and Amgen Inc. (Amgen) announce results from the PATHWAY Phase IIb trial of tezepelumab that showed a significant reduction in the annual asthma exacerbation rate compared with placebo in patients with severe, uncontrolled asthma. Tezepelumab is a first-in-class anti-TSLP monoclonal antibody being developed by MedImmune, AstraZeneca’s global biologics research and development arm, in collaboration with Amgen.
Bristol-Myers Squibb employees ride across the U.S. to raise money to support cancer research by Stand Up To Cancer
- Details
- Category: Bristol-Myers Squibb
The first of seven teams of Bristol-Myers Squibb (NYSE:BMY) employees mounted their bikes in Cannon Beach, OR, today to kick off the 2017 Coast 2 Coast 4 Cancer Ride. Ninety-three novice riders will bike a total of nearly 2,800 miles during the 21-day mission to raise money and awareness for Stand Up To Cancer’s innovative cancer research programs that bring together collaborative teams of scientific researchers to help get new therapies to patients faster.
Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for CyltezoTM (adalimumab-adbm), a biosimilar to Humira®
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) approved CyltezoTM, a biosimilar to Humira®*, in a pre-filled syringe for the treatment of multiple chronic inflammatory diseases, including:
More Pharma News ...
- Abbott and the Abbott Fund donate $1 million to support Hurricane Harvey relief efforts
- Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019)
- Merck collaborates with angiex to speed clinical readiness of new cancer therapy
- AstraZeneca and Takeda establish collaboration to develop and commercialise MEDI1341 for Parkinson's disease
- Victoza® reduces the risk of major cardiovascular events in people with type 2 diabetes with or without prior events
- Boehringer Ingelheim initiates Phase IIa study of compound acquired from Pharmaxis in debilitating liver disease NASH
- Novartis appoints Bertrand Bodson as Chief Digital Officer